Abstract Library

#3030 Targeting CXCR4 and Thioredoxin Reductase in Theranostics of Atypical Carcinoid and Neuroendocrine Carcinoma

Introduction: Atypical carcinoid and small cell lung cancer (SCLC) are currently incurable. There is thus a critical need for new diagnostic and therapeutic strategies for lung neuroendocrine neoplasms (LNEN). Chemokine receptor 4 (CXCR4), a G protein coupled receptor and theranostic target, plays a crucial role in metastases of LNEN. We hypothesize combination of thioredoxin reductase (TR) inhibitor represents a metabolic strategy to enhance cytotoxicity in peptide-receptor radionuclide therapy (PRRT) of LNEN.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Liu D

Authors: Liu D, Fath M, Robles Planells C, Balk E, Bellizzi A,

Keywords: CXCR4, thioredoxin reductase inhibitor, theranostics, atypical carcinoid, small cell lung cancer,

#2022 CXCR4 Expression on Circulating Tumor Cells (CTCs) and Their Association with Bone Metastases in Patients with Neuroendocrine Tumors (NET)

Introduction: Bone metastases have been described in up to 32% of NET patients and are associated with a worse clinical outcome. Overexpression of CXCR4 in primary tumors appears predictive of skeletal involvement.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Rizzo F, Vesely C, Childs A, Mandair D, Khan M,

Keywords: CTC, CXCR4, bone,

#1864 Analysis of mTOR, CXCR4 and PD-1 Checkpoint Pathways in Merkel Cell Neuroendocrine Carcinomas: Correlations with Prognosis and Viral Status

Introduction: Merkel cell carcinoma (MCC) is a rare and aggressive cutaneous neuroendocrine tumor. Prognostic factors currently included in the reference AJCC classification are mainly clinical.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Benhamou J, Deschamps L, Vergier B, Pham-Ledard A, Carlotti A,

Keywords: Merkel cell carcinoma, mTor, CXCR4, PD-L1,

#1847 CXCR4 Inhibition by Ulocuplumab Prevents EMT of pNET Cells in Vitro

Introduction: Neuroendocrine tumors (NETs) overexpress CXCR4. We have previously shown that stimulation of CXCR4 by its ligand SDF-1 promotes the epithelial-mesenchymal transition (EMT) and increases distant tumor spread. Ulocuplumab (Ulo) is a fully human IgG4 mAb designed to inhibit the binding of CXCR4 to SDF-1.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Quaresmini D

Authors: Quaresmini D, Cives M, Pellè E, Ungaro A, Felici C,

Keywords: pNET, CXCR4, EMT, Ulocuplumab,

#1723 Evaluation of the Somatostatin and CXCR4 Chemokine Receptor Expression in Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NEN) of Different Origin

Introduction: Somatostatin receptors (SSTR) are known for their overexpression in well-differentiated GEP-NEN, whereas the chemokine receptor CXCR4 is considered to be present mainly in highly proliferative and advanced tumors.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Lupp A

Authors: Mai R, Kaemmerer D, Sänger J, Neubauer E, Schulz S,

Keywords: somatostatin receptor, CXCR4,